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were not significantly different on MDD-related outpatient services (least-squares 
mean difference[95% CI] for number of outpatient visits: 0.31[-0.01, 0.64]; OR[95% 
CI] for having ≥ 2 outpatient visits: 1.04[0.82, 1.32] for SNRI vs SSRI). ConClusions: 
Chinese physicians seem more likely to choose SNRI than SSRI for the treatment of 
severely-ill MDD patients, as suggested by the patients’ higher likelihood of being 
treated at mental hospitals and having more MDD-related outpatient visits pre-
medication initiation. Although SNRI initiators may be more severely-ill at medica-
tion initiation, they were not found to differ from SSRI initiators on outpatient and 
inpatient service use for MDD in the year following medication initiation.
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objeCtives: Antidepressants use is increasing worldwide but is particularly high 
in Belgium compared to other EU countries whereas suicide-rates in Belgium are 
among the highest. This could reflect misuse of antidepressants resulting in an 
important economic burden. The latter is part of a separate abstract. This study 
assesses the prescribing patterns of antidepressants in Belgium and whether there 
is misuse or not. Methods: Given the efforts to deinstitutionalize mental health 
services, primary care plays now an important role in the diagnosis and treatment 
of mild to moderate mental health disorders. As such, patients treated in 2014 that 
had no prescription with antidepressants in 2013 were analysed from the IMS Health 
Longitudinal Patients Database (IMS Health LPD). The reasons for antidepressant 
prescription and the treatment duration were assessed. The IMS Health LPD, in 
Belgium collects information on diagnosis and prescriptions of a set of 360 general 
practitioners covering about 300,000 patients. Data is collected through an office-
based Electronic Medical Records software. Results: IMS Health LPD showed that 
60% of patients taking antidepressants receive it for depression. The next most 
frequent diagnosis was sleeping disorders (17%) and anxiety (7.5%). Moreover, of 
the patients with depression, 16% received only 1 prescription of an antidepressant 
covering at maximum a month of treatment. This can be considered insufficient 
given the mode of action of these drugs (treatment effect only starts after three 
weeks). ConClusions: Real world data on Belgian antidepressants prescription 
clearly shows that antidepressants are used outside the generally accepted indica-
tions and, when used in the correct indication for a too short time period. By improv-
ing prescribing patterns of antidepressants mental health indicators might improve.
PMH49
THe econoMic consequences of THe use of AnTidePressAnTs in 
BelgiuM
Caekelbergh K, Ramos M, Lamotte M
IMS Health, Vilvoorde, Belgium
objeCtives: Antidepressants use is increasing worldwide but is particularly high 
in Belgium compared to other EU countries whereas suicide-rates in Belgium are 
among the highest. This could reflect misuse of antidepressants resulting in an 
important economic burden. The former is part of a separate abstract. The aim 
here was to evaluate potential savings that could be realized in case prescrip-
tions behavior in Belgium would be similar to neighbor countries. Methods: 
Current spending levels for antidepressants and mood stabilizer prescriptions 
were determined in Belgium, France and the Netherlands. Volume and value sales 
were determined per country (average number of pills sold/capita) based on IMS 
Health Belgian National Retail Database available to IMS Health in both countries 
via the IMS MIDAS platform (2013 data). The potential country-level prescription 
cost in Belgium was estimated by multiplying average number of pills/person 
in France and the Netherlands, with the cost/pill in Belgium and extrapolating 
the result to the total population in Belgium, assuming that prescribing levels in 
Belgium were equal to those in France and the Netherlands and using Belgian 
prices. Results: In Belgium the number of pills per capita is respectively 45% 
and 48% higher compared to France and the Netherlands (34.17 vs. 23.62 vs. 23.15 
pills/person). With a 30% smaller population than the Netherlands, spending in 
Belgium is 4 times higher. In France, having a 6 times larger population compared 
to Belgium, spending is only 3 times higher. The estimated savings for the Belgian 
payer applying the usage (pill/person) of respectively France and the Netherlands 
and current cost/pill in Belgium were € 67 and € 70 Mn, meaning around 30% of 
current spending in Belgium. ConClusions: By comparing Belgium’s prescrip-
tion patterns to France and the Netherlands, we estimated important potential 
savings due to antidepressant mis-use/over-use that could be re-invested in for 
example mental health prevention.
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objeCtives: Depression is the most common psychiatric disease in the world that 
has a reactive environmental character, where the atmosphere can provide this 
disease. The objective of this study was to identify the types of drug treatments 
for depression, in 2014, with data from the health insurance of Brazil. Methods: 
The patients were identified through the health insurance database of Brazil, 
from January to December 2014, who bought some antidepressants medication 
in the analyzed period. From the date of the purchase, it was possible to obtain 
a methodology capable of identifying the age of these patients and the main 
molecules used for the treatment. Results: From a total of 884.143 patients who 
used any type of antidepressant, it was found that 85 % of these patients used the 
following molecules: Fluoxetine (19.0%), Sertraline (18.6%), Escitalopram (14.1%), 
Paroxetine (12.8 %), Bupropion (11.1%) and Amitriptyline (9.5%). Considering the 
age of these patients it was identified that from the age of 30, the incidence in the 
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objeCtives: The objective of the study is to provide utilization data for lisdexam-
fetamine dimesylate (LDX) following its launch in 2013 in Europe for treatment of 
attention deficit hyperactivity disease (ADHD). Methods: This is a multi-country 
drug utilization study using database analysis. Longitudinal EMR databases (Disease 
Analyzer, Germany and CPRD, United Kingdom), National Registries (Denmark, 
Sweden), prescription databases using pharmacy retail data (IFAK/New Index, 
Switzerland) and cross-sectional databases (Prescribing Insights Spain, Switzerland) 
were used. The study includes all patients in the databases who have been pre-
scribed LDX at least once during the study period (March [first EU launch] 2013 – 
December 2014). Results: The majority of patients treated with LDX were males 
in all six European countries studied: Germany (84% in Paediatrician Panel, 78% in 
Neurology/Psychiatry panel), UK (82%), Spain (87%), Denmark (63%), Sweden (60%) 
and Switzerland (75%). Less than 1% of all patients were < 6 years in all countries 
studied. The proportion of patients treated with LDX > 18 years of age was estimated 
to be 12% in Germany (Neurology/Psychiatry Panel Germany), 12% in the UK (CPRD), 
45% in Denmark, 60% in Sweden and 70% in Switzerland. Prescribed average daily 
dose (ADD) of LDX was within the recommended range (30-70mg) for 97% to 100% of 
the patients, with a mean ADD of 44mg in Germany, 48mg in UK and about 44mg in 
Sweden. In Denmark and Switzerland, the recommended dose was not recorded on 
the prescription. ConClusions: Overall, the findings indicate that LDX is mainly 
prescribed within the EMA-approved Summary of Product Characteristics with 
regard to the indicated patients and dose regimen. Adult use is more common in 
Switzerland where use of LDX was already licensed for adults in 2014, or in Denmark 
and Sweden where use of LDX is indicated for adults as of 2015. Prescribed use in 
patients less than 6 years is ≤ 1%.
PMH46
AnTidePressAnT use in PATienTs wiTH MAjor dePressive disorder:  
A coMPArison of TreATMenT resisTAnT And non-TreATMenT resisTAnT 
ePisodes in THe uniTed KingdoM using THe cPrd dATABAse
Kubitz N1, Potluri R2, Mehra M3
1Janssen-Cilag GmbH, Neuss, Germany, 2SmartAnalyst Inc., New York, NY, USA, 3Global Market 
Access & Commercial Strategy Organization, Raritan, NJ, USA
objeCtives: A subset of patients with Major Depressive Disorder (MDD) who are 
treated with, but do not respond to antidepressant and/or antipsychotic (ADAP) 
drugs/ mood stabilizers are characterized as progressing to treatment resistant 
depression (TRD). This study characterized TRD and non-TRD episodes among 
MDD patients in the UK Clinical Practice Research Datalink (CPRD) during 2000-
2012. Methods: Business rules centered on diagnosis and use of antidepressants 
were used to identify new MDD episodes. Treatment regimens were defined as 
mono- or combination therapy with concurrently administered ADAP drugs. TRD 
was defined as ≥ 2 distinct failed regimens in an episode. Adults 18 to 65 years of 
age were included. Results: Of the 427,467 MDD patients, 291,388 (68.2%) were 
excluded because they lacked an index diagnosis date, met an exclusion diagno-
sis criterion, did not meet the age criteria, or had missing age or gender; 136,079 
patients (31.8%) were retained. A total of 6,311 (5.1%) distinct episodes with ≥ 1 ADAP 
prescription were treatment-resistant, with 6,221 (5.9%) of all patients experienc-
ing ≥ 1 TRD episode. Median time to developing TRD was < 11 months (307 days). 
Mean duration of a TRD episode was 1,239 days versus only 305 days for non-TRD 
episodes. Nearly half (46%) of all TRD episodes had up to 4 lines of treatment (LOTs); 
in contrast, only 19% of non-TRD episodes with ≥ 1 ADAP prescription had > 1 LOT. 
Use of combination drug regimens was seen in 46.6% of TRD episodes compared 
with 12.8% of drug-treated non-TRD episodes. TRD episodes were associated with 
higher electroconvulsive therapy exposure, more psychiatrist visits and behavioral 
therapy sessions versus non-TRD episodes. More TRD patients suffered from co-
morbidities such as anxiety and panic disorder. ConClusions: This analysis of 
data from the largest provider of health care in the UK highlights the significant 
burden of TRD on patients and providers.
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objeCtives: To compare baseline characteristics and major depressive disorder 
(MDD)-related healthcare resource use during the 1-year post-medication initia-
tion of patients with MDD who were initiated on selective-noradrenaline-reup-
take inhibitor (SNRI) compared to selective-serotonin-reuptake inhibitor (SSRI) in 
Beijing. Methods: Data from the Beijing Urban Employee Basic Medical Insurance 
Database from July 1, 2011-December 31, 2013, were used. Patients diagnosed with 
MDD were identified using ICD-10th F32/F33. The first-diagnosis date in 2012 was 
designated as the index date. Patients were aged ≥ 18 years; without comorbid can-
cer, schizophrenia, or bipolar disorder; and with 12-months continuous enrollment. 
Logistic regression with stepwise-effect-selection method and multivariate analy-
ses were performed. Results: A total of 4769 patients were included, with 8.6% 
initiated on SNRI. Compared with SSRI initiators, SNRI initiators were more likely 
to be treated at mental than general hospitals (Odds ratio (OR) [95% confidence 
interval (CI)]: 1.96[1.58, 2.42]), had more MDD-related outpatient visits during the 
6-month pre-index date (1.18[1.11, 1.25]), and were more likely to be treated at 
tier-3 hospitals (0.15[0.06, 0.41] for tier 1 vs 3; 0.50[0.36, 0.69] for tier 2 vs 3). In the 
year following medication initiation, few patients (0.5%) experienced MDD-related 
hospitalizations in either medication initiation group. The SNRI and SSRI initiators 
